Distinguished in Osteosarcoma

Weibin J. Zhang

Shanghai, CN 
Distinguished in Osteosarcoma
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Weibin Zhang practices in Shanghai, China. Zhang is rated as a Distinguished expert by MediFind in the treatment of Osteosarcoma. Their top areas of expertise are Osteosarcoma, Adult Soft Tissue Sarcoma, Bone Tumor, Splenic Neoplasm, and Splenectomy.

Their clinical research consists of co-authoring 48 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 28 articles and participated in 2 clinical trials in the study of Osteosarcoma.

Locations

Shanghai, 200025, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II Study of Gemcitabine-docetaxel Chemotherapy With Anti-angiogenic Therapy for Pulmonary Resectable Metastases of Osteosarcoma
A Phase II Study of Gemcitabine-docetaxel Chemotherapy With Anti-angiogenic Therapy for Pulmonary Resectable Metastases of Osteosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: November 01, 2023
Intervention Type: Drug
Study Drugs: Apatinib, GD regimen
Study Phase: Phase 2
A Pilot Study of Circulating Exosome RNA as Diagnostic and Prognostic Markers in Lung Metastases of Primary High-Grade Osteosarcoma
A Pilot Study of Circulating Exosome RNA as Diagnostic and Prognostic Markers in Lung Metastases of Primary High-Grade Osteosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2023
Intervention Type: Other
A Randomized, Double Blind, Multi Center, Active-controlled, 2 Treatment Arm, Parallel Group Non Inferiority Study to Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Versus 1.16% Gel in Subjects With Acute Ankle Sprain
A Randomized, Double Blind, Multi Center, Active-controlled, 2 Treatment Arm, Parallel Group Non Inferiority Study to Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Versus 1.16% Gel in Subjects With Acute Ankle Sprain
Enrollment Status: Completed
Publish Date: April 12, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3
View 2 Less Clinical Trials

48 Total Publications

Thiazolidinones as Potential PGK1 Inhibitors for Treatment of Osteosarcoma Growth and Metastasis.
Thiazolidinones as Potential PGK1 Inhibitors for Treatment of Osteosarcoma Growth and Metastasis.
Journal: Journal of medicinal chemistry
Published: October 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhang's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile